Latest news

• Novartis negotiates ex-US rights to Spark gene therapy

  Luxturna is the first gene therapy to be approved in the US where it has a similar indication - biallelic RPE65-mediated inherited retinal disease (IRD) - and is being launched at a ... No otherwise healthy child should have to go blind due to this

• Spark sets Luxturna price, igniting US affordability debate

  Luxturna is used to treat a sight-robbing disorder called biallelic RPE65-mediated inherited retinal disease (IRD), which affects somewhere between 1, 000 and 2, 000 people in the US with

• Spark’s Luxturna becomes US’s first approved gene therapy

  biallelic RPE65-mediated inherited retinal disease (IRD). ... a policy framework - including the development of disease-specific guidance - “for the evaluation and review of gene therapy.”.

• Spark closes on first US gene therapy approval

  FDA starts review of Luxturna for patients with inherited retinal disease. ... Luxturna (voretigene neparvovec) is under review for a condition known as biallelic RPE65-mediated inherited retinal disease (IRD), which affects around 3, 500 people in the